CELL INTELLIGENCE · 肿瘤细胞治疗研究

使用多等位基因 MHC I 结合系统靶向肽抗原

Targeting peptide antigens using a multiallelic MHC I-binding system.

USP1 去泛素化介导的 CXCR4 上调促进食管鳞状细胞癌的肿瘤发生和免疫逃逸

CXCR4 up-regulation mediated by USP1 deubiquitination promotes the tumorigenesis and immune escape in esophageal squamous-cell carcinoma.

探讨 NY-ESO-1 表达和 HLA 亚型在转移性滑膜肉瘤中的预后影响

Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma.

原发肿瘤队列在调整重要预后因素后，未显示 NY-ESO-1 表达与 OS 之间存在关联（包括按 HLA-A∗02 亚型和治疗线数进行分层），这可能是由于样本量较小所致。

滑膜肉瘤 TCR-T 细胞治疗与冷冻消融前后的组织学评估：一例病例报告

Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation: A Case Report.

TCR-T 治疗后复发的滑膜肉瘤中 β-catenin 上调，可能参与 T 细胞排斥和对 TCR-T 治疗的耐药。

评估 NY-ESO-1 特异性 TCR T 细胞在 HLA-A∗02:01 晚期软组织肉瘤患者中安全性与疗效的 I 期临床试验

Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma.

NY-ESO-1 特异性 TCR 工程化 T 细胞疗法联合淋巴结靶向纳米颗粒肽疫苗治疗晚期软组织肉瘤的 I 期试验

A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatm

晚期和转移性滑膜肉瘤治疗中新兴的靶向和细胞疗法

Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma.

改良 T 细胞对肉瘤的免疫治疗

Immunotherapy of sarcomas with modified T cells.

工程化癌症抗原特异性 T 细胞以克服 TGF-β的免疫抑制效应

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.